Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.15 | 0.02 | 0.00 |
| FCF Yield | -52.86% | -32.14% | -146.71% | -30.22% |
| EV / EBITDA | -1.92 | -3.11 | -0.21 | -2.51 |
| Quality | ||||
| ROIC | -98.50% | -40.44% | -53.14% | -49.78% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.99 | 0.86 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -29.58% | -22.01% | -19.82% | -32.86% |
| Safety | ||||
| Net Debt / EBITDA | -0.25 | -0.16 | 0.40 | 0.36 |
| Interest Coverage | 18.72 | -22.70 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -10.23 | -16.97 |
| Cash Conversion Cycle | 0.00 | -328.89 | -824.58 | -852.13 |